See below to download the Meeting Impression

The role of PCSK9 inhibitors as a novel strategy to reduce LDL-c was addressed in this educational program chaired by Wolfgang Koenig and Michel Farnier at the ESC Congress 2017 in Barcelona, Spain. John Chapman, Kees Hovingh, and Peter Sever discussed the need for additional LDL-c lowering therapies in patients with familial hypercholesterolemia (FH) and the mechanisms and potential applications of therapies, including PCSK9-based therapies, to lower LDL-c in combination with statins or without in statin-intolerant patients. Moreover, evidence from recent trials of novel agents, the need for outcomes data from clinical trials, and the implications of new therapies for future management were presented.

Educational information

The educational objectives of this symposium were to:

• Understand the unmet need for additional LDL-C-lowering therapies beyond current optimal statin-based therapy as a strategy for addressing lipid-related CV risk in patients at increased CV risk and with FH
• Understand the mechanisms and potential applications of emerging therapies to lower LDL through novel approaches that can be used in combination with statin therapy
• Describe the potential impact of PCSK9-based therapies in development in patients who require additional LDL-C reduction
• To explore treatment options in a statin-intolerant high risk patient in order to reach LDL-C goal
• Compare and evaluate evidence from recent clinical trials of novel agents in clinical development and assess their impact on lipids and cardiovascular risk
• Emphasize the need for outcomes data from clinical trials to apply implications and recommendations for practical lipid management
• Understand the implications of new ESC guidelines for lipid management

Faculty

• Prof. John Chapman - Paris, France: Understanding new PCSK9 outcome data: From the LDL-c hypothesis to LDL-c causality
• Prof. Kees Hovingh - Amsterdam, The Netherlands: PCSK9 inhibition across a wide spectrum of patients: One size fits all?
• Prof. Peter Sever - London, United Kingdom: PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials

Disclosures

This satellite symposium was organised by the PACE Foundation and sponsored by an unrestricted educational grant of Amgen and Sanofi-Regeneron.

Download Meeting Impression View lectures - PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies